tetano
Editor, Senior Moderator
SAGE Open Med Case Rep
. 2021 Jun 30;9:2050313X211029699.
doi: 10.1177/2050313X211029699. eCollection 2021.
Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review
Carlos A Flores-Oria[SUP] 1 [/SUP], Emilio Saturno[SUP] 2 [/SUP], Supriya Ramanathan[SUP] 3 [/SUP], Diana J Martinez Castillo[SUP] 3 [/SUP], Roshni Kumar[SUP] 4 [/SUP], Nelson Ferrer[SUP] 5 [/SUP], Afnan Mossaad[SUP] 6 [/SUP], Maria E Tellez[SUP] 7 [/SUP], Cindy Jon[SUP] 1 [/SUP], Sara C Waters[SUP] 6 [/SUP], Ricardo A Mosquera[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 has infected and caused the death of an alarming number of individuals worldwide. No specific treatment has been internationally standardized for coronavirus disease 2019 (COVID-19); however, in some cases, intravenous immunoglobulin (IVIG) has been used as adjuvant treatment in critically ill patients with COVID-19 pneumonia. We report a case of a 50-year-old man with severe COVID-19 pneumonia who received 5 days course of IVIG as adjuvant therapy. Invasive respiratory support was avoided. The patient had a successful recovery and was discharged without supplemental oxygen. A high dose of IVIG may improve survival in patients with severe COVID-19 pneumonia. In the current report, we reviewed literature on how IVIG use may improve the early stages of the disease.
Keywords: Coronavirus disease 2019; IVIG; hypoxemia; intravenous immunoglobulin; severe acute respiratory syndrome coronavirus 2.
. 2021 Jun 30;9:2050313X211029699.
doi: 10.1177/2050313X211029699. eCollection 2021.
Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review
Carlos A Flores-Oria[SUP] 1 [/SUP], Emilio Saturno[SUP] 2 [/SUP], Supriya Ramanathan[SUP] 3 [/SUP], Diana J Martinez Castillo[SUP] 3 [/SUP], Roshni Kumar[SUP] 4 [/SUP], Nelson Ferrer[SUP] 5 [/SUP], Afnan Mossaad[SUP] 6 [/SUP], Maria E Tellez[SUP] 7 [/SUP], Cindy Jon[SUP] 1 [/SUP], Sara C Waters[SUP] 6 [/SUP], Ricardo A Mosquera[SUP] 1 [/SUP]
Affiliations
- PMID: 34262773
- PMCID: PMC8252403
- DOI: 10.1177/2050313X211029699
Abstract
Severe acute respiratory syndrome coronavirus 2 has infected and caused the death of an alarming number of individuals worldwide. No specific treatment has been internationally standardized for coronavirus disease 2019 (COVID-19); however, in some cases, intravenous immunoglobulin (IVIG) has been used as adjuvant treatment in critically ill patients with COVID-19 pneumonia. We report a case of a 50-year-old man with severe COVID-19 pneumonia who received 5 days course of IVIG as adjuvant therapy. Invasive respiratory support was avoided. The patient had a successful recovery and was discharged without supplemental oxygen. A high dose of IVIG may improve survival in patients with severe COVID-19 pneumonia. In the current report, we reviewed literature on how IVIG use may improve the early stages of the disease.
Keywords: Coronavirus disease 2019; IVIG; hypoxemia; intravenous immunoglobulin; severe acute respiratory syndrome coronavirus 2.